Synergy Pharmaceuticals (SGYP) Shares Gap Down to $0.28

Shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) gapped down before the market opened on Wednesday . The stock had previously closed at $0.29, but opened at $0.28. Synergy Pharmaceuticals shares last traded at $0.28, with a volume of 1376034 shares changing hands.

Several equities analysts have recently issued reports on the stock. BTIG Research downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Friday, October 26th. Canaccord Genuity cut shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company’s stock. Synergy Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $5.33.

The company has a market capitalization of $70.24 million, a PE ratio of -0.27 and a beta of 4.94.

Institutional investors have recently bought and sold shares of the stock. B. Riley Wealth Management Inc. acquired a new stake in shares of Synergy Pharmaceuticals during the third quarter worth about $171,000. Vanguard Group Inc. grew its stake in Synergy Pharmaceuticals by 5.9% in the third quarter. Vanguard Group Inc. now owns 22,025,593 shares of the biopharmaceutical company’s stock valued at $37,444,000 after purchasing an additional 1,224,873 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Synergy Pharmaceuticals by 2.6% during the 3rd quarter. BlackRock Inc. now owns 22,300,724 shares of the biopharmaceutical company’s stock worth $37,910,000 after acquiring an additional 568,670 shares during the period. Chicago Equity Partners LLC boosted its stake in Synergy Pharmaceuticals by 153.5% in the 3rd quarter. Chicago Equity Partners LLC now owns 472,535 shares of the biopharmaceutical company’s stock valued at $803,000 after purchasing an additional 286,135 shares during the period. Finally, Nexthera Capital LP bought a new stake in Synergy Pharmaceuticals in the 3rd quarter valued at $1,269,000. Institutional investors and hedge funds own 37.22% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Synergy Pharmaceuticals (SGYP) Shares Gap Down to $0.28” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.com-unik.info/2019/02/13/synergy-pharmaceuticals-sgyp-shares-gap-down-to-0-28.html.

About Synergy Pharmaceuticals (NASDAQ:SGYP)

Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.

Read More: What are the benefits of a balanced fund?

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit